3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. (September 2015) - Stahel, R.A.; Dafni, U.; Gautschi, O.; Felip, E.; Curioni-Fontecedro, A.; Peters, S.; Massutí, B.; Cardenal, F.; Aix, S.P.; Früh, M.; Pless, M.; Popat, S.; et al.